Andrew is a partner and focusses on investments into Healthcare and Life Sciences. He led Inflexion’s investments into Upperton Pharma Solutions, Proteros and TPP and has been involved with a number of Inflexion’s majority and minority investments including Medivet, Movera, CNX Therapeutics and Rosemont since joining in 2016.
Prior to Inflexion, Andrew was an Investment Director at Octopus Investments focussing on Healthcare deals, and prior to that an Assistant Director at GI Partners, also focussed on the healthcare sector. Andrew began his career in the M&A team at PwC.
Outside of work, Andrew enjoys mountain biking, winter sports and paddle boarding.
Andrew has a first class masters in mechanical engineering from Sheffield university.
60 Seconds with
Andrew
0:00
